Drug-Induced Liver Injury - Symptoms, Causes, Treatment & Prevention

```html

Overview

Drug‑Induced Liver Injury (DILI) is liver damage that occurs as an unintended side‑effect of prescription medications, over‑the‑counter (OTC) drugs, herbal supplements, or dietary products. The liver is the body’s primary detoxification organ, so it is especially vulnerable to toxic metabolites produced by many pharmaceutical agents.<sup>1</sup> DILI can present as a mild, transient elevation in liver enzymes or progress to severe hepatitis, cirrhosis, and even acute liver failure.

Who it affects: DILI can occur at any age, but certain groups are more susceptible:

• Older adults (≥65 years) – polypharmacy and reduced hepatic reserve.
• Women – many studies show a 1.5‑ to 2‑fold higher incidence, possibly due to sex‑related metabolic differences.<sup>2</sup>
• Patients with pre‑existing liver disease, obesity, diabetes, or viral hepatitis.
• Individuals who take multiple drugs simultaneously (drug‑drug interactions).

Prevalence: In the United States, DILI accounts for roughly 10 % of all acute hepatitis cases and is the leading cause of acute liver failure in otherwise healthy adults, responsible for an estimated 50,000–100,000 hospital admissions each year.<sup>3,4</sup> Worldwide, the incidence varies between 2–19 cases per 100,000 persons annually, reflecting differences in drug prescribing habits and genetic susceptibility.<sup>5</sup>

Symptoms

DILI can mimic any form of liver disease. Symptoms may appear within days to several months after starting a medication. Not all patients experience symptoms; many are identified through routine lab monitoring.

Common clinical manifestations

• Fatigue or weakness – often the earliest, nonspecific sign.
• Jaundice – yellowing of the skin and sclera due to elevated bilirubin.
• Right‑upper‑quadrant abdominal pain – may feel like a dull ache or pressure.
• Dark urine – caused by conjugated bilirubin excreted by the kidneys.
• Pale, clay‑colored stools – reduced bile flow into the gastrointestinal tract.
• Nausea, vomiting, loss of appetite – common with hepatocellular injury.
• Pruritus (itching) – itching without rash, linked to bile salt accumulation.
• Fever or chills – may accompany an inflammatory or immune‑mediated reaction.
• Elevated liver enzymes on routine blood work – often the first clue in asymptomatic patients.

Less frequent but serious signs

• Hepatic encephalopathy (confusion, asterixis, somnolence) – indicates liver failure.
• Portal hypertension signs (ascites, variceal bleeding).
• Coagulopathy (easy bruising, prolonged bleeding time) due to reduced clotting factor synthesis.

Causes and Risk Factors

DILI is classified by the pattern of liver injury and the underlying mechanism.

Major drug categories implicated

• Antibiotics – amoxicillin‑clavulanate, isoniazid, fluoroquinolones.
• Antiepileptics – valproic acid, carbamazepine, phenytoin.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – diclofenac, ibuprofen.
• Statins – atorvastatin, rosuvastatin (mostly mild elevations; severe injury is rare).
• Herbal & dietary supplements – kava, green tea extract, pyrrolizidine‑alkaloid‑containing plants.
• Immunomodulators & biologics – methotrexate, infliximab.

Mechanisms of injury

1. Direct (dose‑dependent) toxicity – predictable damage from high concentrations (e.g., acetaminophen overdose).<sup>6</sup>
2. Idiosyncratic (dose‑independent) reactions – unpredictable, often immune‑mediated; can occur at therapeutic doses.
3. Metabolic activation – the drug is converted into a reactive metabolite that binds cellular proteins.
4. Mitochondrial dysfunction – impairment of energy production leading to cell death.

Risk‑enhancing factors

• Genetic polymorphisms (e.g., HLA‑B*57:01 for flucloxacillin hepatotoxicity).<sup>7</sup>
• Pre‑existing liver disease (viral hepatitis, non‑alcoholic fatty liver disease).
• Alcohol consumption – synergistic toxicity with many drugs.
• Obesity & metabolic syndrome – alter drug metabolism.
• Concomitant use of multiple hepatotoxic agents.
• Prenatal or post‑menopausal hormone therapy (estrogen‑containing drugs increase cholestatic risk).

Diagnosis

Diagnosing DILI is largely one of exclusion – clinicians must rule out viral hepatitis, autoimmune liver disease, ischemic injury, and other causes. The process typically involves a detailed medication history, laboratory assessment, imaging, and occasionally liver biopsy.

Step‑by‑step diagnostic approach

1. Medication timeline – document every prescription, OTC, supplement, and the start/stop dates.
2. Baseline and serial liver function tests (LFTs) – AST, ALT, ALP, GGT, total and direct bilirubin, INR.
3. Serology & viral studies – hepatitis A, B, C, E; CMV; EBV; HIV if risk factors present.
4. Autoimmune screen – antinuclear antibody (ANA), anti‑smooth muscle, IgG levels.
5. Imaging – abdominal ultrasound (rules out biliary obstruction), CT or MRI if needed.
6. Scoring systems – RUCAM (Roussel Uclaf Causality Assessment Method) helps quantify the likelihood that a drug caused the injury.<sup>8</sup>
7. Liver biopsy – reserved for unclear cases or when alternative diagnoses (e.g., autoimmune hepatitis) cannot be excluded.

Key laboratory patterns

Pattern	Predominant enzyme elevation	Typical causes
Hepatocellular	ALT >5× ULN, ALT >2× ALP	Acetaminophen, isoniazid, halothane
Cholestatic	ALP >2× ULN, ALT <2× ULN	Amoxicillin‑clavulanate, steroids, oral contraceptives
Mixed	Both ALT and ALP elevated	Valproic acid, methotrexate

Treatment Options

Management focuses on removing the offending agent, supporting liver function, and preventing progression.

Immediate steps

• Discontinue the suspected drug – the most critical intervention; in many cases liver enzymes improve within 1‑2 weeks.
• Consider alternative therapy – discuss with the prescribing physician to replace the drug with a safer option.

Pharmacologic therapies

• N‑acetylcysteine (NAC) – proven antidote for acetaminophen toxicity; also beneficial in non‑acetaminophen DILI with acute liver failure.<sup>9</sup>
• Corticosteroids – used for immune‑mediated DILI (e.g., drug‑induced autoimmune hepatitis) after ruling out infection.
• Ursodeoxycholic acid (UDCA) – may improve cholestatic injury, though evidence is modest.

Supportive care

• Hydration and electrolyte balance.
• Nutritional support – high‑protein, low‑fat diet if tolerated.
• Monitoring for encephalopathy, coagulopathy, and renal dysfunction.

Advanced interventions

• Liver transplant – reserved for fulminant failure (MELD score >30, refractory encephalopathy, or multiorgan failure).
• Artificial liver support systems – Molecular adsorbent recirculating system (MARS) may bridge patients to recovery or transplant.

Living with Drug‑Induced Liver Injury

After the acute phase, most patients can return to normal life with vigilant follow‑up.

Daily management tips

1. Medication review – keep an updated list; ask pharmacists to flag hepatotoxic drugs.
2. Regular LFT monitoring – at baseline, 2‑4 weeks after drug cessation, then quarterly for 6 months.
3. Balanced diet – emphasis on fruits, vegetables, whole grains, and lean protein; limit saturated fat and added sugars.
4. Alcohol moderation – ideally abstain while the liver recovers; if you drink, keep ≤1 drink/day for women and ≤2 for men.
5. Maintain a healthy weight – weight loss improves fatty infiltration and overall liver resilience.
6. Vaccinations – Hepatitis A and B vaccines are recommended for all with chronic liver disease.
7. Stay active – at least 150 minutes of moderate aerobic activity per week.

Follow‑up schedule

• First visit: 2 weeks after drug discontinuation – repeat LFTs, discuss symptoms.
• Subsequent visits: every 1‑3 months until enzymes normalize, then semi‑annual for 1 year.
• Long‑term: yearly assessment if any residual enzyme elevation or fibrosis is present.

Prevention

Preventing DILI hinges on judicious prescribing, patient education, and early detection.

For healthcare providers

• Use the lowest effective dose and shortest duration for known hepatotoxins.
• Screen for liver disease before initiating high‑risk drugs (e.g., baseline ALT/AST).
• Employ drug‑interaction checkers and pharmacogenomic testing when available (e.g., HLA‑B*57:01 before flucloxacillin).
• Educate patients about warning signs and the importance of reporting new symptoms promptly.

For patients

• Never self‑medicate with herbal supplements without consulting a clinician.
• Adhere strictly to prescribed doses; avoid “doubling up” on acetaminophen‑containing products.
• Inform all providers (including dentists and urgent‑care clinicians) about any known drug allergies or prior liver issues.
• Keep a medication diary, especially when starting a new drug.

Complications

If DILI is not recognized early, it can progress to serious, sometimes irreversible conditions.

Potential complications

• Acute liver failure (ALF) – rapid loss of hepatic function; mortality >30 % without transplant.
• Chronic hepatitis & fibrosis – persistent inflammation may lead to cirrhosis over years.
• Portal hypertension – ascites, variceal bleeding, hepatic encephalopathy.
• Hepatocellular carcinoma (HCC) – risk increases in patients who develop cirrhosis.
• Extra‑hepatic immune phenomena – rash, eosinophilia, renal interstitial nephritis.

When to Seek Emergency Care

---

References

1. Mayo Clinic. Drug-Induced Liver Injury. 2023. https://www.mayoclinic.org
2. US Food and Drug Administration. Drug-Induced Liver Injury: Pharmacovigilance and Sex Differences. 2022.
3. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Gastroenterol Hepatol. 2022;19(1):63‑75.
4. European Association for the Study of the Liver (EASL). Guidelines on drug‑induced liver injury. 2023.
5. World Health Organization. Global surveillance of drug‑induced liver injury. WHO Technical Report Series, No. 1029, 2021.
6. Lee WM. Acetaminophen toxicity: new insights into hepatic repair. J Clin Gastroenterol. 2021;55(5):382‑388.
7. US National Library of Medicine. HLA‑B*57:01 and flucloxacillin hepatotoxicity. 2020.
8. Danan G, Teschke R. RUCAM in drug‑induced liver injury: update and future directions. Int J Mol Sci. 2022;23(8):4051.
9. Rahman A et al. N‑acetylcysteine for non‑acetaminophen acute liver failure: systematic review. Clin Gastroenterol Hepatol. 2023;21(4):735‑744.

```